Tramadol (Ultram) is prescribed to relieve moderate to moderately severe pain, to treat pain caused by surgery and chronic conditions such as cancer or joint pain. It works by decreasing the body’s sense of pain.
Gelonida is a narcotic analgesic used to treat or prevent moderate to severe pain.
* Most important fact about Tramadol (Ultram)
You should not drive a car, operate machinery, or perform any other potentially hazardous activities until you know how Tramadol Ultram affects you.
It’s important to take Tramadol exactly as prescribed. Do not increase the dosage or length of time you take Ultram without your doctor’s approval.
Side effects cannot be anticipated. If any develop or change in intensity, tell your doctor as soon as possible. Only your doctor can determine if it is safe for you to continue taking Ultram.
Side effects may include:
Agitation, anxiety, bloating and gas, constipation, convulsive movements, diarrhea, dizziness, drowsiness, dry mouth, feeling of elation, hallucinations, headache, indigestion, itching, nausea, nervousness, sweating, tremor, vomiting, weakness.
Less serious side effects may include:
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Avoid Tramadol Ultram if it has ever given you an allergic reaction. Also avoid Tramadol Ultram after taking large doses of sleeping pills such as Halcion, Dalmane, and Restoril; narcotic pain relievers such as Demerol, morphine, Darvon, and Percocet; or psychotherapeutic drugs such as antidepressants and tranquilizers. And do not take Tramadol Ultram after drinking excessive amounts of alcohol.
If you have stomach problems such as an ulcer, make sure your doctor is aware of them. Tramadol Ultram may hide the symptoms, making them difficult to diagnose and treat.
Tramadol Ultram can cause mental and physical addiction. If you’ve ever had a problem with narcotic painkillers such as Percocet, Demerol, or morphine, you should avoid Tramadol Ultram. Withdrawal symptoms may occur if you stop taking Tramadol Ultram abruptly. Such symptoms include anxiety, sweating, insomnia, pain, nausea, tremor, diarrhea, and respiratory problems. A gradual decrease in dosage will help prevent these symptoms.
Do not take more than the recommended dose of Tramadol Ultram, since larger doses have been known to cause seizures, especially if you have epilepsy or are taking medications that also increase the risk of seizures. Among such medications are almost all antidepressant drugs, plus narcotics and major tranquilizers such as Loxitane and Stelazine.
If you have liver or kidney disease, be sure your doctor knows about it. Your dosage may have to be reduced.
Before you have any kind of surgery, make sure the doctor knows you are taking Tramadol Ultram.
If you have any kind of breathing problem, use Tramadol Ultram with caution or take a different kind of painkiller. Tramadol Ultram can impair respiration, especially if taken with alcohol.
If you have experienced a head injury, consult your doctor before taking Tramadol Ultram. The medication’s effects may be stronger and could hide warning signs of serious trouble.
Tramadol Ultram may increase the drowsiness caused by alcohol. Do not drink alcohol while taking Tramadol Ultram.
There have been reports of serious harm to developing babies when Tramadol Ultram was used during pregnancy. If you are pregnant or plan to become pregnant, tell your doctor immediately.
Tramadol Ultram appears in breast milk and may affect a nursing infant. If Tramadol Ultram is essential to your health, your doctor may advise you to discontinue breastfeeding until your treatment is finished.
Avoid Tramadol Ultram, too, if you are taking the seizure medication Tegretol.
Symptoms of Ultram overdose include:
Difficult or slowed breathing, drowsiness, coma, seizures, cardiac arrest. Tramadol can be habit-forming. Do not take a larger dose, take it more often, or take it for a longer period of time than prescribed by your doctor.
***** Gelonida *****
Gelonida - generic name is parecoxib sodium. It is used to treat or prevent moderate to severe pain.
* Side effects
That may go away during treatment, include drowsiness, dizziness, constipation, or nausea. If they continue or are bothersome, check with your doctor.
Check with your doctor if you experience vomiting, skin rash, itching, slowed or difficult breathing, difficulty urinating, or fainting.
Don’t take this drug if you are also taking Quinidine. Inform your doctor of any other medical conditions, allergies, pregnancy, or breast-feeding.
If overdose is suspected, contact your local poison control center or emergency room immediately. Symptoms of overdose may include cold and clammy skin, slowed breathing, slowed heartbeat, drowsiness, dizziness, lightheadedness, deep sleep, and loss of consciousness.
Avoid alcohol while you are using this drug. This drug will add to the effects of alcohol and other depressants.
Don’t drive, don’t operate machinery until you know how you react to this medicine? Using this medicine alone, with other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks.
Don’t take this drug if you have had a severe allrgic reaction to Codeine, Hydrocodone, Dihydrocodeine, or Oxycodone (such as Tylox, Tylenol with Codeine, Vicodin).
A severe allergic reaction includes a severe rash, hives, breathing difficulties, or dizziness.
Tags: Chronic Conditions, Narcotic Painkillers, Restoril
Tags: Medwatch, Oral Administration, Release Tablets
The purpose of this study is to compare the administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages versus tramadol IV given in 3 unit dosage of 35 mg during the first 6 hours postoperatively and to investigate the time course and accuracy of pain relief versus the onset and duration of side effects. The first unit dose will be administered at arrival at the PACU when a Visual Analogue Pain (VAS) score of more than 3 is reached. The second and third unit dose will be administered after 1 and 2 hours, respectively, when a VAS of more than 3 is observed.
| Condition | Intervention | Phase |
| Pain | Drug: Tramadol per os (Tradonal Odis® orodispersible tablets) Drug: Tramadol IV (Tradonal® IV) |
Phase IV |
| Drug Information available for: | Tramadol hydrochloride Tramadol |
U.S. FDA Resources
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Comparison of the Therapeutic Efficacy and Side Effects of Tramadol Per os (Tradonal Odis® Orodispersible Tablets) Versus an Optimised Dosis of Intravenous Tramadol for Postoperative Pain Relief in Ambulatory Surgery. |
| Estimated Enrollment: | 200 |
| Study Start Date: | March 2008 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
| 1: Experimental
Tramadol per os (Tradonal Odis® orodispersible tablets)
|
Drug: Tramadol per os (Tradonal Odis® orodispersible tablets)
Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
|
| 2: Active Comparator
Tramadol IV (Tradonal® IV)
|
Drug: Tramadol IV (Tradonal® IV)
Administration of tramadol IV given in 3 unit dosage of 35 mg
|
Tags: Ambulatory, Pain, Relief, Surgery, Tramadol
Purpose
Tramadol is a largely used analgesic drug. Its role however on sensitization as occurs for example in neuropathic pain is not very well known. This protocol aims therefore at studying the effect of tramadol in a human pain model with sensitization induced by a cold stimulus, using evoked potentials to elucidate how pain is modified when tramadol is administered.
| Condition | Intervention | Phase |
| Pain | Drug: Tramadol | Phase I |
| Drug Information available for: | Tramadol hydrochloride Tramadol |
U.S. FDA Resources
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Pharmacodynamics Study |
| Official Title: | Tramadol and Pain Sensitization |
| Estimated Enrollment: | 12 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | December 2007 |
| Estimated Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Detailed Description:
The study is a comparison of the analgesic of tramadol versus placebo in a pain model using evoked potentials. Evaluation criteria will be the amplitude of the evoked potential obtained defore and after treatment
Tags: Amplitude, cold stimulus, Pain, placebo, sensitization, Tramadol